Ocugen, Inc. (OCGN) announced that Health Canada has provided it a No Objection Letter to initiate the phase III liMeliGhT study evaluating its modifier gene therapy product candidate, OCU400, for treating retinitis pigmentosa (RP). Shares of OCGN were up 4.6% on Aug. 26 following the announcement of the news. Ocugen has already received clearance from the FDA to initiate a phase III study on OCU400 for the treatment of RP, a rare genetic disorder that can lead to vision loss and blindness. The FDA had prev ...